

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer, its management, as well as financial statements. No public offer of securities is to be made by the Issuer in the United States.*



## **Yestar Healthcare Holdings Company Limited**

**巨星醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2393)**

**NOTICE OF SCHEME EFFECTIVE DATE  
IN THE GRAND COURT OF THE CAYMAN ISLANDS  
FINANCIAL SERVICES DIVISION  
CAUSE NO. FSD 0391 OF 2023 (JAJ)  
IN THE MATTER OF SECTION 86 OF  
THE COMPANIES ACT (2023 REVISION)  
AND  
IN THE MATTER OF YESTAR HEALTHCARE HOLDINGS  
COMPANY LIMITED (巨星醫療控股有限公司)**

This announcement is made by Yestar Healthcare Holdings Company Limited (巨星醫療控股有限公司) (the “**Company**”) pursuant to Rules 13.09(2) and 37.47(B) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of the Company dated 24 January 2024 and 20 February 2024 in relation to the notice of the Scheme Meeting and the results of the Scheme Meeting (collectively, the “**Announcements**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as in the Announcements.

## **SANCTION OF THE SCHEME**

The Company is pleased to announce that, by an order dated 28 February 2024 (the “**Cayman Sanction Order**”), the Grand Court of the Cayman Islands sanctioned the Scheme without modification.

## **EFFECTIVE DATE OF THE SCHEME**

A copy of the sealed Cayman Sanction Order was delivered to the Registrar of Companies for registration on 29 February 2024 (Cayman Islands time) and the Scheme Effective Date has accordingly occurred on 29 February 2024 (Cayman Islands time).

This Notice is circulated in accordance with clause 7.5 of the Scheme.

For further information, please contact the Information Agent or the Company, in each case, using the contact details below:

Scheme Creditors (who are not Blocked Scheme Creditors) may contact:

### **Morrow Sodali Limited**

#### **Address:**

In Hong Kong: 29/F, No. 28 Stanley Street, Central, Hong Kong  
In London: 103 Wigmore Street, W1U 1QS, London, United Kingdom

Phone: Hong Kong: +852 2319 4130/London: +44 20 4513 6933

Transaction Website (document posting website):

<https://projects.morrowsodali.com/yestar>

Scheme AHL Portal (for submission of the Account Holder Letter):

<https://portal.morrowsodali.com/yestarAHL>

Email: [yestar@investor.morrowsodali.com](mailto:yestar@investor.morrowsodali.com)

Blocked Scheme Creditors may contact:

**Yestar Healthcare Holdings Company Limited**

Address: Suite 2105, 21/F Central Plaza, 18 Harbour Road, Hong Kong

Phone: +852 3422 8938

Email: [bond@yesstarnet.com.cn](mailto:bond@yesstarnet.com.cn)

**Shareholders and potential investors should note that the successful implementation of the proposed restructuring is still subject to the satisfaction or waiver of certain conditions precedent. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board

**Yestar Healthcare Holdings Company Limited**

**Liao Changxiang**

*CEO and Executive Director*

1 March 2024

*As at the date of this announcement, the executive Directors are Ms. Liao Changxiang, Ms. Wang Hong and Mr. Liang Junxiong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Mr. Zeng Jinsong, Mr. Zhao Ziwei and Mr. Koeswondo Michael David.*